Search Within

Subhiksha Nandakumar

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Journal Article (26)
  2. Meeting Abstract (19)
  3. Correspondence (1)
  4. Research Letter (1)
Groups
  1. GSK Faculty (47)
  2. Human Oncology and Pathogenesis Program (47)
  3. Department of Medicine (35)
  4. Department of Pathology and Laboratory Medicine (35)
  5. Solid Tumor Oncology Division (35)
  6. Epidemiology and Biostatistics (34)

More Groups

People
  1. Nikolaus Schultz (30)
  2. Michael Berger (22)
  3. David Solit (20)
  4. Ingo Mellinghoff (17)
  5. Angela Brannon (15)
  6. Marc Ladanyi (15)

More People

Years
  1. 2025 (4)
  2. 2024 (14)
  3. 2023 (7)
  4. 2022 (11)
  5. 2021 (2)
  6. 2020 (7)

More Years

Publications
  1. Clinical Cancer Research (9)
  2. Neuro-Oncology (7)
  3. Cancer Research (6)
  4. Journal of Clinical Oncology (4)
  5. Cancer Discovery (2)
  6. European Urology (2)

More Publications

Publishers
  1. American Association for Cancer Research (18)
  2. Oxford University Press (8)
  3. Nature Publishing Group (5)
  4. American Society of Clinical Oncology (4)
  5. Elsevier Inc. (2)
  6. Elsevier Science, Inc. (2)

More Publishers

Results (47)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Specific mutations in APC, but not alterations in DNA damage response, associate with outcomes of patients with metastatic colorectal cancer
    Journal Article

    Mondaca, S.; Walch, H.; Nandakumar, S.; Chatila, W. K.; Schultz, N.; Yaeger, R.
    Gastroenterology (2020)

    Fulltext@MSK | Save
  • Pan-cancer analysis of CDK12 alterations identifies a subset of prostate cancers with distinct genomic and clinical characteristics
    Journal Article

    Nguyen, B.; Mota, J. M.; Nandakumar, S.; Stopsack, K. H.; Weg, E.; Rathkopf, D.; Morris, M. J.; Scher, H. I.; Kantoff, P. W.; Gopalan, A.; more...
    European Urology (2020)

    Fulltext@MSK | Save
  • Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer
    Journal Article

    Mazzu, Y. Z.; Armenia, J.; Nandakumar, S.; Chakraborty, G.; Yoshikawa, Y.; Jehane, L. E.; Lee, G. S. M.; Atiq, M.; Khan, N.; Schultz, N.; more...
    Molecular Oncology (2020)

    Fulltext@MSK | Save
  • Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer
    Journal Article

    Stopsack, K. H.; Nandakumar, S.; Wibmer, A. G.; Haywood, S.; Weg, E. S.; Barnett, E. S.; Kim, C. J.; Carbone, E. A.; Vasselman, S. E.; Nguyen, B.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Significance of BRCA2 and RB1 co-loss in aggressive prostate cancer progression
    Journal Article

    Chakraborty, G.; Armenia, J.; Mazzu, Y. Z.; Nandakumar, S.; Stopsack, K. H.; Atiq, M. O.; Komura, K.; Jehane, L.; Hirani, R.; Chadalavada, K.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Influence of WNT and DNA damage response pathway alterations on outcomes in patients with unresectable metastatic colorectal cancer
    Meeting Abstract

    Mondaca, S.; Walch, H. S.; Nandakumar, S.; Chatila, W. K.; Hechtman, J. F.; Cercek, A.; Diaz, L. A.; Sanchez-Vega, F.; Kemeny, N. E.; Segal, N. H.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Prospective genotyping of hepatocellular carcinoma: Clinical implications of next-generation sequencing for matching patients to targeted and immune therapies
    Journal Article

    Harding, J. J.; Nandakumar, S.; Armenia, J.; Khalil, D. N.; Albano, M.; Ly, M.; Shia, J.; Hechtman, J. F.; Kundra, R.; El Dika, I.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save